DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Thrombocytopenia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Thrombocytopenia (204)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include thrombocytopenia. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 204   Next >>

Possible Cyclophosphamide side effects in 65 year old female

Reported by a physician from Japan on 2012-08-24

Patient: 65 year old female, weighing 50.2 kg (110.6 pounds)

Reactions: Weight Decreased, Blood Bilirubin Increased, Cytomegalovirus Viraemia, Headache, Pyrexia, Interstitial Lung Disease, Oedema, Thrombocytopenia, Blood Sodium Decreased, Decreased Appetite, Vomiting, Stomatitis, Pneumonia, Alanine Aminotransferase Increased, Lymphopenia, Anaemia, Febrile Neutropenia, Rash, Blood Phosphorus Decreased, Blood Potassium Decreased, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Leukopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 30 mg/m2 x 1/4 week
    Start date: 2011-03-16

Adriamycin PFS
    Dosage: 40 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Carboplatin
    Dosage: 250 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Cyclophosphamide
    Dosage: 350 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Etoposide
    Dosage: 100 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Prednisolone
    Dosage: 1mg/kg x 1/2 week
    Start date: 2011-12-13
    End date: 2011-12-14

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Start date: 2011-03-16

Prednisolone
    Dosage: 2 mg/m2, 1x/day
    Administration route: Oral
    Start date: 2011-03-24

Ranimustine
    Dosage: 60 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-16

Vincristine Sulfate
    Dosage: 1 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Vindesine Sulfate
    Dosage: 2.4 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Other drugs received by patient: Mucosolvan; Lansoprazole; Sulfamethoxazole and Trimethoprim; Armodafinil; Zolpidem; Olopatadine HCL; Cefazolin Sodium; Ciprofloxacin HCL; Armodafinil; Zovirax; Magmitt; Alendronate Sodium



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Cyclophosphamide side effects in 44 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21

Patient: 44 year old female

Reactions: Squamous Cell Carcinoma, Carbohydrate Antigen 125 Increased, Thrombocytopenia

Drug(s) suspected as cause:
ABT-888
    Administration route: Oral
    Indication: Ovarian Cancer
    Start date: 2010-06-01
    End date: 2011-04-01

Carboplatin
    Dosage: x 3 days for 4 cycles
    Indication: Ovarian Cancer
    Start date: 2007-07-13
    End date: 2007-09-14

Cisplatin
    Dosage: x 3 days for 4 cycles
    Indication: Ovarian Cancer
    Start date: 2005-06-14
    End date: 2005-08-10

Cyclophosphamide
    Indication: Ovarian Cancer
    Start date: 2010-06-01
    End date: 2011-04-01

Doxorubicin Hydrochloride
    Dosage: maintenance dose for a total cumulative dose of 1.696 mg
    Indication: Ovarian Cancer
    End date: 2010-04-01

Doxorubicin Hydrochloride
    Dosage: 3 cycles given
    Start date: 2007-07-13
    End date: 2007-09-14

Paclitaxel
    Dosage: x 3 days for 4 cycles
    Indication: Ovarian Cancer
    Start date: 2007-07-13
    End date: 2007-09-14

Topotecan Hydrochloride
    Start date: 2005-08-29

Topotecan Hydrochloride
    Dosage: for 4 cycles
    Indication: Ovarian Cancer
    Start date: 2005-06-14
    End date: 2005-08-02



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-16

Patient: female

Reactions: Hepatic Pain, Hyperthermia, Bicytopenia, Weight Increased, Renal Failure, Hepatomegaly, Respiratory Failure, Staphylococcal Infection, Oliguria, Thrombocytopenia, Fluid Retention

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 3900 mg, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-03

Methotrexate
    Dosage: 17.6 mg, unk
    Start date: 2012-06-13

Methotrexate
    Dosage: 26.5 unk, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-08

Methotrexate
    Dosage: 17.6 mg, unk
    Start date: 2012-06-10

Thymoglobulin
    Dosage: 0.5 mg/kg, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-04

Thymoglobulin
    Dosage: 2.5 mg/kg, unk
    Start date: 2012-06-06

Thymoglobulin
    Dosage: 2 mg/kg, unk
    Start date: 2012-06-05



Possible Cyclophosphamide side effects in female

Reported by a consumer/non-health professional from France on 2012-08-14

Patient: female

Reactions: Hepatic Pain, Hyperthermia, Bicytopenia, Weight Increased, Hepatomegaly, Renal Failure, Staphylococcal Infection, Respiratory Failure, Oliguria, Thrombocytopenia, Fluid Retention

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 3900 mg, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-03

Methotrexate
    Dosage: 17.6 mg, unk
    Start date: 2012-06-10

Methotrexate
    Dosage: 17.6 mg, unk
    Start date: 2012-06-13

Methotrexate
    Dosage: 26.5 unk, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-08

Thymoglobulin
    Dosage: 0.5 mg/kg, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-04

Thymoglobulin
    Dosage: 2 mg/kg, unk
    Start date: 2012-06-05

Thymoglobulin
    Dosage: 2.5 mg/kg, unk
    Start date: 2012-06-06



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13

Patient: female

Reactions: Hepatomegaly, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Bone Marrow Transplant
    Start date: 2012-04-03
    End date: 2012-04-04

Cyclophosphamide
    Start date: 2012-06-03
    End date: 2012-06-04

Methotrexate
    Start date: 2012-06-10
    End date: 2012-06-10

Methotrexate
    Indication: Bone Marrow Transplant
    Start date: 2012-06-08
    End date: 2012-06-08

Methotrexate
    Start date: 2012-06-13
    End date: 2012-06-13

Thymoglobulin
    Indication: Bone Marrow Transplant
    Start date: 2012-06-04
    End date: 2012-06-06



Possible Cyclophosphamide side effects in

Reported by a physician from Netherlands on 2012-08-07

Patient:

Reactions: Diabetes Mellitus, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-07-16

Dexamethasone
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-07-16

Velcade
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-07-16

Other drugs received by patient: Omeprazole; Fluconazole; Zelitrex / 01269701 /; Ciproxin / 00697201 /; Metoclopramide



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-07-27

Patient: female, weighing 67.7 kg (148.9 pounds)

Reactions: Febrile Neutropenia, Neutropenia, Bronchitis, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-24

Cyclophosphamide
    Start date: 2012-04-12

Epirubicin Hydrochloride
    Start date: 2012-05-24

Epirubicin Hydrochloride
    Start date: 2012-04-12

Fluorouracil
    Start date: 2012-04-12

Fluorouracil
    Start date: 2012-05-24

Other drugs received by patient: Nobiten; Pantoprazole; Simvastatine EG; Escitalopram Oxalate



Possible Cyclophosphamide side effects in

Reported by a physician from Italy on 2012-07-27

Patient:

Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Epirubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone and Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in 46 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-27

Patient: 46 year old female

Reactions: Pancreatic Infarction, Unresponsive To Stimuli, Myelodysplastic Syndrome, Pyrexia, Pallor, Cerebral Haemorrhage, Skin Discolouration, Diarrhoea Haemorrhagic, Small Intestinal Haemorrhage, Apnoea, Thrombocytopenia, Cough, Candidiasis, Hepatosplenomegaly, Dyspnoea, Pain in Extremity, Anaemia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Hemisensory Neglect, Lung Infiltration, Asthenia, Hepatic Infarction

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Cytarabine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Etoposide
    Indication: Diffuse Large B-Cell Lymphoma

Idarubicin HCL
    Dosage: 12 mg/m2, unk
    Indication: Myelodysplastic Syndrome

Oncovin
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Suberoylanilide Hydroxamic Acid
    Dosage: 500 mg, tid
    Administration route: Oral
    Indication: Myelodysplastic Syndrome

Other drugs received by patient: Radiotherapy



Possible Cyclophosphamide side effects in 77 year old female

Reported by a physician from United States on 2012-07-24

Patient: 77 year old female, weighing 63.0 kg (138.7 pounds)

Reactions: Dyspnoea, Dysgeusia, Fatigue, Bronchial Disorder, Pleural Effusion, Weight Fluctuation, Neutropenia, Asthenia, Thrombocytopenia, Cardiac Failure Congestive

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: iv
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-05-01

Matulane
    Dosage: 100 mg;qd;po
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-05-21

Prednisone TAB
    Dosage: po
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-05-01

Rituximab
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-05-01

Sodium Nitroprusside
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-05-01



Possible Cyclophosphamide side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: 100 mg on days 1-5 for chop and r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 375 mg/m2 on day 1 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient:

Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 milligram/sq. meter
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Revlimid
    Dosage: 15 milligram
    Administration route: Oral

Velcade
    Dosage: 1.3 milligram/sq. meter
    Indication: Multiple Myeloma

Velcade
    Dosage: 1.3 milligram/sq. meter



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from United States on 2012-07-11

Patient:

Reactions: Weight Decreased, Thrombosis, Pruritus, Hypokalaemia, Fatigue, Depression, Thrombocytopenia, Alanine Aminotransferase Abnormal, Blood Antidiuretic Hormone Abnormal, Dyspnoea, Nausea, Lymphopenia, Haemoglobin Abnormal, Hyponatraemia, Febrile Neutropenia, Palmar-Plantar Erythrodysaesthesia Syndrome, Rash, Diarrhoea, Embolism, Blood Alkaline Phosphatase Abnormal, Dehydration, Neutropenia, Leukopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on days 1-14
    Administration route: Oral
    Indication: Breast Cancer Metastatic

Xeloda
    Dosage: beginning on day 8 and continuing to day 21 (total of 14 days)
    Administration route: Oral
    Indication: Breast Cancer Metastatic



Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from Japan on 2012-07-09

Patient: female

Reactions: Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Thrombocytopenia, Leukopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for metastatic patients
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: as adjuvant therapy

Docetaxel
    Indication: Breast Cancer

Epirubicin Hydrochloride
    Dosage: adjuvant therapy
    Indication: Breast Cancer

Fluorouracil
    Dosage: adjuvant therapy

Fluorouracil
    Dosage: adjuvant therapy
    Indication: Breast Cancer

Herceptin
    Indication: Breast Cancer

Methotrexate
    Indication: Breast Cancer

Paclitaxel

Paclitaxel
    Indication: Breast Cancer

Vinorelbine Tartrate
    Indication: Breast Cancer

Xeloda
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-06

Patient:

Reactions: Stomatitis, Hepatic Failure, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Haematotoxicity, Cardiac Disorder, Neutropenia, Thrombocytopenia, Renal Failure Acute

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxil
    Dosage: cohort 1: 20 mg/m2 cohort ii: 25 mg/m2 cohort iii: 30 mg/m2
    Indication: Diffuse Large B-Cell Lymphoma

Neulasta
    Dosage: on day 2 of a 14 day cycle
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: day 1-5
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 2 mg max
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in female

Reported by a physician from Germany on 2012-07-06

Patient: female

Reactions: Presyncope, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1483 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Dosage: 100 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Rituxan
    Dosage: 742.5 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Vincristine
    Dosage: 3.94 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Ramipril; Nebivolol; Tiotropium Bromide; Levothyroxine Sodium; Trimethoprim + Sulfamethoxazole; Acyclovir; Simvastatin; Torsemide; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Pantoprazole



Possible Cyclophosphamide side effects in male

Reported by a pharmacist from Netherlands on 2012-07-06

Patient: male, weighing 80.0 kg (176.0 pounds)

Reactions: Colitis, Thrombocytopenia, Leukopenia, Renal Failure Acute

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Multiple Myeloma
    Start date: 2012-05-04

Velcade
    Indication: Multiple Myeloma
    Start date: 2012-05-04

Other drugs received by patient: Fluconazole; Valaciclovir; Dexamethasone; Cotrim



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Velcade
    Dosage: on days 1 and 8

Velcade
    Dosage: on days 1 and 8
    Indication: Chronic Lymphocytic Leukaemia

Velcade
    Dosage: on days 1 and 8
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in 67 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: 67 year old male

Reactions: Weight Decreased, Anaemia, Acute Phosphate Nephropathy, Mental Status Changes, Hypercalcaemia, Hyperuricaemia, Haemodialysis, Tumour Lysis Syndrome, Renal Impairment, Oliguria, Leukocytosis, Thrombocytopenia, Decreased Appetite, Renal Failure Acute, Hepatosplenomegaly

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chemotherapy

Dexamethasone Sodium Phosphate
    Indication: Chemotherapy

Doxorubicin HCL
    Indication: Chemotherapy

Vincristine
    Indication: Chemotherapy



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-06-28

Patient:

Reactions: Neuropathy Peripheral, Adverse Drug Reaction, Neutropenia, Multiple Myeloma, Thrombocytopenia

Drug(s) suspected as cause:
Bortezomib
    Dosage: post-induction therapy, days 1, 8, 15
    Indication: Multiple Myeloma

Bortezomib
    Dosage: induction therapy

Cyclophosphamide
    Dosage: post induction therapy; days 1, 8, 15, 22
    Administration route: Oral
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: induction therapy

Dexamethasone
    Dosage: maintainance therapy
    Indication: Multiple Myeloma

Doxorubicin HCL
    Dosage: induction therapy
    Indication: Multiple Myeloma

Prednisone TAB
    Dosage: post induction therapy; of a 28-day cycle
    Indication: Multiple Myeloma



Possible Cyclophosphamide side effects in female

Reported by a physician from Germany on 2012-06-28

Patient: female

Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Neulasta
    Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Dosage: frequency 1 times in 2 week for 5 days
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole



Possible Cyclophosphamide side effects in

Reported by a physician from France on 2012-06-27

Patient:

Reactions: Febrile Neutropenia, Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma, Thrombocytopenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Granulocyte Colony Stimulating Factor
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Dosage: on days 1-5, every 21 days for 6 cycles
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-27

Patient:

Reactions: Nausea, Chills, Anaemia, Constipation, Neuropathy Peripheral, Fatigue, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Indication: B-Cell Lymphoma

Cyclophosphamide

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Velcade
    Dosage: on days 1 and 8
    Indication: Chronic Lymphocytic Leukaemia

Velcade
    Dosage: on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: on days 1 and 8



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from Korea, Republic of on 2012-06-26

Patient:

Reactions: Abdominal Pain, Hyperbilirubinaemia, Anaemia, Alanine Aminotransferase Increased, Febrile Neutropenia, Rash, Pyrexia, Peripheral Sensory Neuropathy, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Asthenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: given on day 1 of each cycle
    Indication: B-Cell Lymphoma

Mabthera
    Dosage: on day 1 of every cycle
    Indication: B-Cell Lymphoma

Prednisolone
    Dosage: given on days 1 to 5 of every cycle (repeated every 3 weeks)
    Administration route: Oral
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: given on day 1 of every cycle; dose: 1.4 mg/m2 ( maximum 2.0 mg)
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22

Patient:

Reactions: Performance Status Decreased, Pain, Abdominal Pain Upper, Fatigue, Neutropenic Infection, Thrombocytopenia, Hallucination, Dyspnoea, Vomiting, Nausea, Hyperglycaemia, Haemoglobin Abnormal, Pancytopenia, Febrile Neutropenia, Toxicity To Various Agents, Haemoglobin, Neutropenia, Diffuse Large B-Cell Lymphoma, Cardiovascular Disorder, Leukopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Granulocyte Macrophage Colony Stim Factor
    Dosage: days 3-10
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Anti-Emetics; Dapsone; Trimethoprim + Sulfamethoxazole



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-06-22

Patient:

Reactions: Ischaemia, Thrombosis, Hypersensitivity, Adverse Drug Reaction, Rectal Haemorrhage, Headache, Peripheral Sensory Neuropathy, Disease Progression, Cardiac Disorder, Myalgia, Fatigue, Proteinuria, Leukoencephalopathy, Thrombocytopenia, Epistaxis, Dyspnoea, Nausea, Alanine Aminotransferase Increased, Anaemia, Febrile Neutropenia, Mucosal Inflammation, Arthralgia, Aspartate Aminotransferase Increased, Ejection Fraction Decreased, Neutropenia, Hypertension

Drug(s) suspected as cause:
Bevacizumab
    Indication: Breast Cancer

Cyclophosphamide
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 10, 20, 50, 100 or 150mg vials
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Indication: Breast Cancer

Taxol
    Indication: Breast Cancer

Other drugs received by patient: Radiation Therapy NOS; Hormonal Treatment NOS



Possible Cyclophosphamide side effects in male

Reported by a individual with unspecified qualification from Italy on 2012-06-18

Patient: male

Reactions: Epstein-Barr Virus Infection, Diarrhoea, Anaemia, Sepsis, Cytomegalovirus Infection, Neutropenia, Thrombocytopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cisplatin
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Etoposide
    Indication: Burkitt's Lymphoma

Mabthera
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Methylprednisolone
    Indication: Burkitt's Lymphoma

Vincristine Sulfate
    Indication: Burkitt's Lymphoma



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014